Amplia just dropped some seriously hopeful results for their new pancreatic cancer drug, narmafotinib, at ASCO GI. When paired with standard chemo, patients saw better outcomes—think longer progression-free survival and higher response rates—than the usual treatment alone. Plus, it’s well tolerated! With few options for advanced pancreatic cancer, this could be a real game-changer. Fingers crossed for more good news as trials continue! #Health #BodyHealth #CancerResearch